Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2017-05-24 Director's Dealing
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2017-05-24 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC under the Securities Act of 1933. It is a registration statement for the offering and sale of securities, including common stock, by Galectin Therapeutics Inc. The document includes details about the offering, selling stockholders, risk factors, use of proceeds, and plan of distribution. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update filings.
2017-05-19 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes an entry into a material definitive agreement related to an At Market Issuance Sales Agreement for common stock sales, and amendments to the certificate of incorporation regarding preferred and common stock. There are no financial statements or detailed financial performance data included, only announcements of agreements and amendments. This fits the category of Capital/Financing Update (CAP) because it relates to financing activities and changes in capital structure. The document length is 6833 characters, which is sufficient to contain substantive information rather than just a brief announcement. Therefore, the classification is CAP with high confidence.
2017-05-19 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 15, 2017, by Galectin Therapeutics Inc. It announces the results of operations and financial condition for the three months ended May 15, 2017, and includes a press release as an exhibit. The text explicitly states that the information is being furnished under Item 2.02 of Form 8-K, which pertains to 'Results of Operations and Financial Condition.' The document is relatively short (4299 characters) and primarily serves as an announcement of financial results rather than a full financial report. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the appropriate classification is ER with high confidence.
2017-05-15 English
FORM 10-Q
Interim / Quarterly Report Q1 2017
2017-05-15 English
PRIMARY DOCUMENT
Director's Dealing
2017-05-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.